The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
The anti-angiogenic basis of metronomic chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=2064">ERBB2 oncoprotein — which is combined with an alkylating agent or paclitaxel for the treatment of metastatic breast cance”
BackgroundIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“Until 1997, it was thought that all new endothelial cells were derived through the latter proces”
BackgroundComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., Magner, M., Isner, J. M., & Asahara, T. (1999) · Nature Medicine · doi:10.1038/7434 · Cited by 2,423
Principles and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,027
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., & Keshet, E. (1995) · Nature Medicine · doi:10.1038/nm1095-1024 · Cited by 1,604
Cited by
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Self-citationCombination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Self-citationDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
“…doses on a more frequent and regular dosing interval prevents bone marrow toxicity and blocks tumor growth by interfering with angiogenesis (Hahnfeldt et al., 2003), which was thought to result from either inducing apoptosis or decreasing proliferation of endothelial cells (Kerbel and Kamen, 2004).”
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 945
Biological properties of “naked” metal nanoparticles☆
BHATTACHARYA, R., & MUKHERJEE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.013 · Cited by 917
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Unifying niche shift studies: insights from biological invasions
Guisan, A., Petitpierre, B., Broennimann, O., Daehler, C., & Kueffer, C. (2014) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2014.02.009 · Cited by 810
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
FOLKMAN, J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 658
Zeisberger, S. M., Odermatt, B., Marty, C., Zehnder-Fjällman, A. H. M., Ballmer-Hofer, K., & Schwendener, R. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603240 · Cited by 623
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575
Self-citationMacrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Simkens, L. H. J., van Tinteren, H., May, A., ten Tije, A. J., Creemers, G.-J. M., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F. L. G., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 517
Dietrich, J., Han, R., Yang, Y., Mayer-Pröschel, M., & Noble, M. (2006) · Journal of Biology · doi:10.1186/jbiol50 · Cited by 500
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Self-citationZhou, Y., Fan, S., Feng, L., Huang, X., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202104223 · Cited by 463
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
Dickson, P. V., Hamner, J. B., Sims, T. L., Fraga, C. H., Ng, C. Y. C., Rajasekeran, S., Hagedorn, N. L., McCarville, M. B., Stewart, C. F., & Davidoff, A. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0278 · Cited by 441
Shaked, Y., Henke, E., Roodhart, J. M. L., Mancuso, P., Langenberg, M. H. G., Colleoni, M., Daenen, L. G., Man, S., Xu, P., Emmenegger, U., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.001 · Cited by 440
Self-citationClassifying the evolutionary and ecological features of neoplasms
Maley, C. C., Aktipis, A., Graham, T. A., Sottoriva, A., Boddy, A. M., Janiszewska, M., Silva, A. S., Gerlinger, M., Yuan, Y., Pienta, K. J., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.69 · Cited by 423
Fury, M. G., Antonescu, C. R., Van Zee, K. J., Brennan, M. E., & Maki, R. G. (2005) · The Cancer Journal · doi:10.1097/00130404-200505000-00011 · Cited by 413
Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy
Zhang, C., Ni, D., Liu, Y., Yao, H., Bu, W., & Shi, J. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2016.280 · Cited by 413
Folkins, C., Man, S., Xu, P., Shaked, Y., Hicklin, D. J., & Kerbel, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4238 · Cited by 385
Self-citationPhase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Alternative Vascularization Mechanisms in Cancer
Döme, B., Hendrix, M. J. C., Paku, S., Tóvári, J., & Tímár, J. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060302 · Cited by 359
Zeng, Q., Li, S., Chepeha, D. B., Giordano, T. J., Li, J., Zhang, H., Polverini, P. J., Nor, J., Kitajewski, J., & Wang, C.-Y. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.004 · Cited by 360
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Tumor evolution: Linear, branching, neutral or punctuated?
Davis, A., Gao, R., & Navin, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.003 · Cited by 352
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells
Su, J.-L., Yang, P.-C., Shih, J.-Y., Yang, C.-Y., Wei, L.-H., Hsieh, C.-Y., Chou, C.-H., Jeng, Y.-M., Wang, M.-Y., Chang, K.-J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.018 · Cited by 348
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Novel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis
Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz, T., Rawn, K., Voskas, D., Dumont, D. J., Ben-David, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.023 · Cited by 324
Self-citationEndogenous angiogenesis inhibitors
FOLKMAN, J. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0809.x · Cited by 321
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
Metronomics: towards personalized chemotherapy?
André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 320
Metalloproteinases and their inhibitors in tumor angiogenesis
Handsley, M. M., & Edwards, D. R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20945 · Cited by 307
Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options
de Lange, J., van den Akker, H. P., & van den Berg, H. (2007) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2007.04.003 · Cited by 304
Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R., Shaked, Y., Mancuso, P., Goldhirsch, A., Rocca, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4789 · Cited by 293
Differentiation and Definition of Vascular-Targeted Therapies
Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Horsman, M. R., Marmé, D., & LoRusso, P. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.416.11.2 · Cited by 272
Panigrahy, D., Kaipainen, A., Huang, S., Butterfield, C. E., Barnés, C. M., Fannon, M., Laforme, A. M., Chaponis, D. M., Folkman, J., & Kieran, M. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711281105 · Cited by 269
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Luvero, D., Milani, A., & Ledermann, J. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014544121 · Cited by 260
Shaked, Y., Emmenegger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y., & Kerbel, R. S. (2005) · Blood · doi:10.1182/blood-2005-04-1422 · Cited by 253
Self-citationRole of vascular normalization in benefit from metronomic chemotherapy
Mpekris, F., Baish, J. W., Stylianopoulos, T., & Jain, R. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700340114 · Cited by 178
Modulation of the tumor vasculature and oxygenation to improve therapy
Siemann, D. W., & Horsman, M. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.006 · Cited by 169
Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., Greenberger, L. M., & Horak, I. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4456 · Cited by 168
Socinski, M. A., Langer, C. J., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Zhang, H., & Renschler, M. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mds461 · Cited by 108
Tumour endothelial cells acquire drug resistance in a tumour microenvironment
Hida, K., Akiyama, K., Ohga, N., Maishi, N., & Hida, Y. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs152 · Cited by 68
Gebbia, V., Serretta, V., Borsellino, N., & Valerio, M. R. (2011) · Urology · doi:10.1016/j.urology.2011.08.010 · Cited by 38
Liver microsystems in vitro for drug response
Lee, J.-H., Ho, K.-L., & Fan, S.-K. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0575-0 · Cited by 33
Yang, Y., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2022) · doi:10.1101/2022.06.15.492526 · Cited by 2
Metadata
- Authors
- Kerbel, R. S., & Kamen, B. A.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 423-436
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2169965478
- Cited by
- 1,397
- References
- 108
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.